NICE does not recommend Venclyxto for use with Chronic Lymphocytic Leukaemia.- AbbVie + Roche.

The National Institution for Health and Care Excellence (NICE) has in its second draft guidance rejected Venclyxto (venetoclax) from AbbVie/Roche as a treatment for Chronic Lymphocytic Leukaemia (CLL) as it finds there are too many uncertainties in its clinical evidence base and its small study. Venclyxto has a price of �4,800 a month and at this level was not found cost effective. Clinical trial evidence supports using Venclyxto plus rituximab to boost progression free survival compared with bendamustine plus rituximab, but the latter combination is now �rarely used�. Moreover, patients with the 17P deletion or TP53 mutation have alternative treatments available as NICE has already recommended Gilead�s Zydelig (idelalisib) in first line treatment and Imbruvica (ibrutinib)from AbbVie/Janssen in second line for this type of cancer.